1. **Definitions**
   a. “Licensed Technology” means the rights licensed by the University to the Licensee pursuant to [Main Agreement].
   b. “Associated Licensee Rights” means all rights in data, information, know-how, methods, procedures and processes, including patent and marketing rights, possessed by Licensee during the term of this Agreement that are necessary to make, use, sell, offer to sell, import or export an End Product or to perform Neglected Research, including but not limited to biological, chemical, biochemical, toxicological, pharmacological, metabolic, formulation, clinical, analytical and stability information and data.
   c. “Associated Notifier Rights” means all rights in data, information, know-how, methods, procedures and processes, including patent and marketing rights, possessed by a Notifier during the term of the Open License granted to such Notifier that are necessary to make, use, sell, offer to sell, import or export an End Product or to perform Neglected Research, including but not limited to biological, chemical, biochemical, toxicological, pharmacological, metabolic, formulation, clinical, analytical and stability information and data.
   d. “Eligible Country” means any country classified by the World Bank as “Low-income” or “Middle-income” at the time a Notification is made.
   e. “End Product” means any product whose manufacture or use relies upon or is covered by the Licensed Technology.
   f. “Fair Royalty” means:
      i. For countries classified by the World Bank as “Low-income” at the time of the sales on which royalties are due, 2% of Notifier’s Net Sales of End Products in the Notified Country of Net Sales;
      ii. For countries classified by the World Bank as “Middle-income” at the time of the sales on which royalties are due, 5% of Notifier’s the Net Sales of the End Products by the Notifier in the Notified Country in question.
   g. “Licensed Technology” means the rights licensed by University to the Licensee pursuant to [Main Agreement].

---

1 This license is the product of an independent working group, based at Yale University, convened by Universities Allied for Essential Medicines.
h. “Neglected Disease” means any disease, condition, or affliction that, at the time Notification under Section 3.a. is made, either affects less than 200,000 persons in the United States or for which there is no reasonable expectation that the cost of developing and making available in the United States a treatment, prophylaxis, or device for such disease, condition, or affliction can be recovered from sales in the United States of such treatment, prophylaxis, or device.

i. “Neglected Research” means any use of the Licensed Technology or Associated Licensee Rights in an effort to develop treatments, prophylaxis, or devices for a Neglected Disease.

j. “Notification” means a writing that announces the intention of a party to receive an Open License.

k. “Notification Fee” means:
   i. For Notification to receive an Open License to supply End Products to an Eligible Country that is classified by the World Bank as “Low-income” at the time of Notification, $5,000;
   ii. For Notification to receive an Open License to supply End Products to an Eligible Country that is classified by the World Bank as “Middle-income” at the time of Notification, $50,000;
   iii. For Notification to receive an Open License to perform Neglected Research, $500.

l. “Notified Country” means an Eligible Country indicated by a Notifier in a Notification.

m. “Notifier” means a party that has submitted a Notification to the University and Licensee[along with an appropriate Notification Fee]. [University or Licensee acceptance of the Notification and Notification Fee are not required for a party to be a Notifier or for a Notifier to receive an Open License.]

n. “Open License” means a non-exclusive license to the Licensed Technology, Associated Licensee Rights, and Associated Notifier Rights granted by the University to a Notifier from University upon Notification. There are no limitations on the number of Open Licenses that may be received or the parties whom may receive an Open License.

2. **Licensee Grant**: Licensee hereby grants University a license to the Associated Licensee Rights for the sole purpose of granting Open Licenses either to Supply in accordance with Section 3.a. or for Neglected Research in accordance with Section 4.a..
   [The licensee also agrees to include, in any patent application for a Licensee Improvement, a sentence reading: “This patent is subject to the provisions of the Equitable Access and Neglected Disease License.”]
3. Notification to Supply
   a. Grant of Open License to Supply: Upon providing to University and Licensee Notification to receive an Open License to supply End Products to an Eligible Country, a Notifier automatically receives an Open License from the University permitting the making, using, selling, offering to sell, importing, and exporting of End Products in the Notified Country and the making and exporting of End Products in any country other than the Notified Country for the sole purpose of supplying End Products to the Notified Country. If Notifier exercises its right to make and export an End Product in any country other than a Notified Country for the sole purpose of export to a Notified Country, then Notifier shall use reasonable efforts to visibly distinguish the End Product it manufactures from the End Product sold distributed by the Licensee in the country of manufacture, but such reasonable efforts do not require Notifier to expend significant expense.
   b. Fair Royalties: The Open License to supply End Products received by Notifier shall be irrevocable and perpetual so long as Notifier submits to University and Licensee payment of a Fair Royalty on sales of End Products covered by the Licensed Technology or Associated Licensee Rights within 90 days of such sales, such Fair Royalty to be divided equally between University and Licensee. [Failure or refusal of University or Licensee to accept the Fair Royalty shall not terminate or affect in any way the Open License.]
   c. Notifier Grant: In exchange for receipt of an Open License to Supply, Notifier grants University a license to its Associated Notifier Rights for the sole purpose of granting Open Licenses either to Supply in accordance with Section 3.a. or for Neglected Research in accordance with Section 4.a..

4. Notification for Neglected Research
   a. Grant of Open License for Neglected Research: Upon providing to University and Licensee Notification to receive an Open License to perform Neglected Research, a Notifier automatically receives a worldwide, irrevocable, and perpetual Open License from the University to perform Neglected Research.
   b. No Royalty: No royalty shall be payable to either the University or the Licensee for the Open License for Neglected Research.
   c. Notifier Grant: In exchange for receipt of an Open License for Neglected Research, Notifier grants University a license to its Associated Notifier Rights for the sole purpose of granting Open Licenses either to Supply in accordance with
Section 3.a. or for Neglected Research in accordance with Section 4.a..

5. **Assurance of Freedom to Operate**: No license or other transfer of the Licensed Technology or Associated Licensee Rights by the University or Licensee shall be valid unless the terms of this Equitable Access and Neglected Disease License are incorporated therein.

6. **Transparency**: Notwithstanding any other agreement or provision between the parties, either party may publicize the fact that the Licensed Technology and Associated Licensee Rights are subject to a license that includes this Equitable Access License.